N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer.
D000111:Acetylcysteine / Q000008:administration & dosage* / Q000627:therapeutic use; D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D003520:Cyclophosphamide / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006417:Hematuria / Q000139:chemically induced; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D013736:Testicular Neoplasms / Q000188:drug therapy*
D003520:Cyclophosphamide; D007069:Ifosfamide; D000111:Acetylcysteine